194 related articles for article (PubMed ID: 20951320)
1. Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.
Campo G; Fileti L; de Cesare N; Meliga E; Furgieri A; Russo F; Colangelo S; Brugaletta S; Ferrari R; Valgimigli M;
J Am Coll Cardiol; 2010 Oct; 56(18):1447-55. PubMed ID: 20951320
[TBL] [Abstract][Full Text] [Related]
2. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.
Valgimigli M; Campo G; de Cesare N; Meliga E; Vranckx P; Furgieri A; Angiolillo DJ; Sabatè M; Hamon M; Repetto A; Colangelo S; Brugaletta S; Parrinello G; Percoco G; Ferrari R;
Circulation; 2009 Jun; 119(25):3215-22. PubMed ID: 19528337
[TBL] [Abstract][Full Text] [Related]
3. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
[TBL] [Abstract][Full Text] [Related]
4. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris.
Cuisset T; Hamilos M; Sarma J; Sarno G; Wyffels E; Vanderheyden M; Barbato E; Bartunek J; De Bruyne B; Wijns W
Am J Cardiol; 2008 Jun; 101(12):1700-3. PubMed ID: 18549843
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study.
Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G
J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).
Campo G; Valgimigli M; Frangione A; Luccarelli S; Cangiano E; Cavazza C; Fileti L; Ferrari R;
J Am Coll Cardiol; 2010 Jan; 55(3):255-6. PubMed ID: 20117406
[No Abstract] [Full Text] [Related]
7. Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention.
Mangiacapra F; Patti G; Peace A; Gatto L; Vizzi V; Ricottini E; D'Ambrosio A; Muller O; Barbato E; Di Sciascio G
Am J Cardiol; 2010 Sep; 106(5):619-23. PubMed ID: 20723634
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events.
Marcucci R; Paniccia R; Antonucci E; Gori AM; Fedi S; Giglioli C; Valente S; Prisco D; Abbate R; Gensini GF
Am J Cardiol; 2006 Nov; 98(9):1156-9. PubMed ID: 17056317
[TBL] [Abstract][Full Text] [Related]
10. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
12. Drug therapy during percutaneous coronary interventions in stable and unstable coronary artery disease: the Italian Drug Evaluation in Angioplasty (IDEA) study.
Savonitto S; Ambrosini V; Marzocchi A; Tolaro S; Petronio AS; Galassi AR; Bongo AS; Gaglione A; Bolognese L; ;
Ital Heart J; 2005 Feb; 6(2):106-18. PubMed ID: 15819503
[TBL] [Abstract][Full Text] [Related]
13. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
[TBL] [Abstract][Full Text] [Related]
14. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of clopidogrel unresponsiveness during elective coronary stenting: experience with the point-of-care platelet function assay-100 C/ADP.
Moerenhout CM; Claeys MJ; Haine S; Miljoen H; Bosmans JM; Vertessen F; Kluppels K; Van der Planken M; Vrints CJ
Am Heart J; 2010 Mar; 159(3):434-8. PubMed ID: 20211306
[TBL] [Abstract][Full Text] [Related]
16. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
[TBL] [Abstract][Full Text] [Related]
17. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
[TBL] [Abstract][Full Text] [Related]
18. Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Perez de Prado A; Cuellas C; Diego A; de Miguel A; Samaniego B; Alonso-Orcajo N; Carbonell R; Pascual C; Fernandez-Vazquez F; Calabozo RG
Thromb Res; 2009 Dec; 124(6):678-82. PubMed ID: 19411094
[TBL] [Abstract][Full Text] [Related]
19. Effect of tirofiban plus clopidogrel and aspirin on primary percutaneous coronary intervention via transradial approach in patients with acute myocardial infarction.
Fu XH; Hao QQ; Jia XW; Fan WZ; Gu XS; Wu WL; Hao GZ; Li SQ; Jiang YF; Geng W
Chin Med J (Engl); 2008 Mar; 121(6):522-7. PubMed ID: 18364139
[TBL] [Abstract][Full Text] [Related]
20. Long-term reduction of mortality in the 4-year follow up of tirofiban therapy in elective percutaneous coronary interventions (TOPSTAR) trial.
Lengenfelder B; Stoerk S; Boes L; Strotmann J; Ertl G; Voelker W; Bonz AW
J Invasive Cardiol; 2011 Apr; 23(4):128-32. PubMed ID: 21474843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
